Abstract
For many years, it has been recognised that venous thrombo-embolism (VTE) represents a common complication of malignancy. Moreover, VTE in the form of pulmonary embolism (PE) is life-threatening, and constitutes the second leading cause of death in patients with cancer. Consequently, overall survival is significantly reduced in cancer patients who develop thrombosis. In addition, treatment of VTE with anticoagulation is often difficult to manage in the context of cancer. Studies have shown that the risk of recurrent VTE, and the risk of major bleeding are both increased significantly in cancer patients on therapeutic anticoagulant therapy. In this case report, we describe a patient with metastatic carcinoma of the cervix, who developed recurrent thrombotic complications despite being maintained on standard therapeutic doses of both warfarin, and subsequently low molecular weight heparin. However, her refractory VTE was successfully managed using a supra-therapeutic dose low-molecular-weight-heparin (LMWH) regimen, together with close monitoring of plasma anti-Xa levels.
Similar content being viewed by others
Abbreviations
- VTE:
-
Venous thrombo-embolism
- DVT:
-
Deep vein thrombosis
- PE:
-
Pulmonary embolism
- LMWH:
-
Low molecular weight heparin
- INR:
-
International normalised ratio
References
Lyman GH, Khorana AA, Falanga A et al (2007) American society of clinical oncology guideline: recommendations for venous thromboembolism prophylaxis and treatment in patients with cancer. J Clin Oncol 25:5490–5505
Lee AY (2005) Management of thrombosis in cancer: primary prevention and secondary prophylaxis. Br J Haematol 128:291–302
Prandoni P, Lensing AW, Piccioli A et al (2002) Recurrent venous thromboembolism and bleeding complications during anticoagulant treatment in patients with cancer and venous thrombosis. Blood 100:3484–3488
Lee AY, Levine MN, Baker RI et al (2003) Low molecular weight heparin versus a coumarin for the prevention of recurrent venous thromboembolism in patients with cancer. N Engl J Med 349:146–153
White RH (2003) Low molecular weight heparins: are they all the same? Br J Hameatol 121:12–20
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Cunningham, M.S., Gilmore, R., O’Donnell, D. et al. Management of refractory venous thrombosis associated with malignancy using a supra-therapeutic enoxaparin regimen. Ir J Med Sci 178, 339–341 (2009). https://doi.org/10.1007/s11845-008-0200-9
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s11845-008-0200-9